动物造模,透明细胞肾癌裸鼠模型 z-bio 2021-06-03 920

　　OBJECTIVE: To use patient-derived clear cell renal cell carcinoma (ccRCC) cells (patient-derived cells, PDC) to establish a patient-derived tumor xenograft model (PDX model), and to detect the sensitivity of ccRCCPDC to molecularly targeted drugs. That theory. Experimental basis for clinical diagnosis and treatment.

　　Method: Inoculate ccRCCPDCs subcutaneously into nude mice, and use molecular targeted drugs to establish tumor models. Oral sunitinib (sunitinib), sorafenib (sorafenib), lenvatinib (lenvatinib), regorafenib (regorafenib), apatinib (regorafenib), apatinib (apatinib) and anal Rotinib (anrotinib), the drug's inhibitory effect on subcutaneous tumors of ccRCCPDCs in nude mice. Collect cell and tumor tissue samples, use quantitative PCR technology to detect molecular targeted drug targets (receptor tyrosine protein kinases such as VEGFR and protein kinases such as ERK and AKT belonging to the MAPK signaling pathway) to determine the genetic background of those under test Is ccRCCPDC stable?

　　Result: We successfully obtained 5 strains of ccRCCPDC, inoculated nude mice with the above-mentioned ccRCCPDCs, and obtained a nude mouse kidney cancer subcutaneous tumor model. Although molecular targeted drugs have decreased or disappeared, the expression of molecular targeted drugs in tumor tissues is relatively stable due to the expansion of PDCs due to the occurrence of tumors in nude mice, and the subcutaneous inhibitory effect of molecular targeted drugs is nude mouse tumors. The formation of mouse ccRCCPDCs has obvious individual differences in the source of patients. Among the selected targeted therapies, lembatinib has stronger anti-tumor activity than some other targeted therapies. ...

　　Conclusion: In this study, we successfully established a kidney cancer animal model using a clear cell renal cell carcinoma cell line from a patient, and tested the sensitivity of renal cancer cells to molecular targeted drugs. This can provide theoretical and experimental basis for related clinical diagnosis and treatment. .